Jeff Haxer
Associé,
Merger & Acquisition (M&A) expert in our Healthcare practice, including pharma, medical devices and insurance
À propos de Jeff
Expertise
- Expert in our M&A and Healthcare practices
- Leader of dozens of corporate and PE due diligence assessments, multiple post-merger integration assignments and several complex separations/carve-outs
- Co-author of Bain's POV on successful spin-offs as published in HBR
Jeff Haxer is the global leader of Bain's Divestitures and Spin-offs product. Previously, he led the M&A group within our Americas Healthcare and Life Sciences practice.
Jeff has led 40+ corporate and PE due diligence assessments, and advised on 25+ acquisition, divestiture, and spin-off transactions with a cumulative value of $200B+.
His industry experience includes pharmaceuticals (small and large molecule), medical devices, healthcare payer, healthcare provider, automotive, insurance, distribution (cold chain and non-cold chain), packaging (rigid and flexible), retail, restaurant and agriculture.
Jeff earned an MBA from the MIT Sloan School of Management and a BBA, with honors, from the University of Michigan.
Recent Insights
- “Finding the Right Deals in Pharma M&A Now,” Infographic, 17 avril 2023
- “Corporate M&A: Pressing “Pause”,” Global Healthcare Private Equity and M&A Report, 10 avril 2023, Rapport
- “Healthcare and Life Sciences M&A,” M&A Report, 31 janvier 2023, Rapport
- “Few Corporate Spinoffs Deliver Value,” Harvard Business Review, 20 décembre 2022, Article
- “Investor Relations: How to Get the Valuation You Deserve ,” Webinar, 31 mars 2022